For US residents only.

RYDAPT IS FDA APPROVED
INDICATIONS for RYDAPT® (midostaurin) capsules:

RYDAPT is an oral prescription medicine used in combination with certain chemotherapy medicines to treat adults with newly diagnosed acute myeloid leukemia (AML) who have a defect in a gene called FLT...

See More
IMPORTANT SAFETY INFORMATION for RYDAPT® (midostaurin) capsules
Allergic Reactions
  • Do not take RYDAPT if you are allergic to midostaurin or any of the ingredients in RYDAPT
  • If you develop signs of an allergic reaction, seek medical help immediately
  • Signs of an allergic reaction include trouble breathing, flushing, chest pain, throat tightness, and sw...
See More
Learn More About

Treatment Information

Learn more about an FDA-approved treatment for patients with newly diagnosed FLT3-positive acute myeloid leukemia and for patients with 3 types of systemic mastocytosis (SM).*

Learn More
Learn More About

Patient
Support

Novartis is committed to helping patients gain access to the treatment they need. Click below for more information about how to access RYDAPT support programs.

Learn More

*Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL) are collectively referred to as advanced SM.